{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T21:39:13Z","timestamp":1768513153650,"version":"3.49.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,12,19]],"date-time":"2017-12-19T00:00:00Z","timestamp":1513641600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"National Institute of Allergy and Infectious Diseases of the National Institutes of Health"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.vaccine.2017.12.046","type":"journal-article","created":{"date-parts":[[2017,12,26]],"date-time":"2017-12-26T18:24:50Z","timestamp":1514312690000},"page":"683-690","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Alphavirus vector-based replicon particles expressing multivalent cross-protective Lassa virus glycoproteins"],"prefix":"10.1016","volume":"36","author":[{"given":"Min","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jenny","family":"Jokinen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irina","family":"Tretyakova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Pushko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Igor S.","family":"Lukashevich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2017.12.046_b0005","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1007\/s00705-015-2418-y","article-title":"Past, present, and future of arenavirus taxonomy","volume":"160","author":"Radoshitzky","year":"2015","journal-title":"Arch Virol"},{"issue":"3","key":"10.1016\/j.vaccine.2017.12.046_b0010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0000388","article-title":"Risk maps of lassa fever in West Africa","volume":"3","author":"Fichet-Calvet","year":"2009","journal-title":"PLoS Negl Trop Dis"},{"issue":"8","key":"10.1016\/j.vaccine.2017.12.046_b0015","doi-asserted-by":"crossref","first-page":"e100711","DOI":"10.1371\/journal.pone.0100711","article-title":"Mapping transmission risk of Lassa fever in West Africa: the importance of quality control, sampling bias, and error weighting","volume":"9","author":"Peterson","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2017.12.046_b0020","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1863-2378.2012.01469.x","article-title":"Lassa fever in West Africa: evidence for an expanded region of endemicity","volume":"59","author":"Sogoba","year":"2012","journal-title":"Zoonoses Public Health"},{"issue":"7426","key":"10.1016\/j.vaccine.2017.12.046_b0025","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1136\/bmj.327.7426.1271","article-title":"Lassa fever: epidemiology, clinical features, and social consequences","volume":"327","author":"Richmond","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2017.12.046_b0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coviro.2013.04.007","article-title":"Vaccines for viral hemorrhagic fevers - progress and shortcomings","volume":"3","author":"Falzarano","year":"2013","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.vaccine.2017.12.046_b0035","unstructured":"WHO. 2017 Annual review of diseases prioritized under the Research and Development Blueprint, Geneva, Switzerland. <http:\/\/wwwwhoint\/csr\/research-and-development\/documents\/2017-Prioritization-Long-Reportpdf?ua=1.2017> (24-25 January 2017)."},{"key":"10.1016\/j.vaccine.2017.12.046_b0040","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/BF01310811","article-title":"Ribonucleic acids of Machupo and Lassa viruses","volume":"79","author":"Lukashevich","year":"1984","journal-title":"Arch Virol"},{"key":"10.1016\/j.vaccine.2017.12.046_b0045","doi-asserted-by":"crossref","first-page":"351","DOI":"10.2174\/138920206778948673","article-title":"Lassa virus genome","volume":"7","author":"Lukashevich","year":"2006","journal-title":"Curr Genom"},{"key":"10.1016\/j.vaccine.2017.12.046_b0050","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.3390\/v4102162","article-title":"Envelope glycoprotein of arenaviruses","volume":"4","author":"Burri","year":"2012","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2017.12.046_b0055","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1586\/14760584.3.2.189","article-title":"Lassa fever vaccine: a review","volume":"3","author":"Fisher-Hoch","year":"2004","journal-title":"Expert Rev Vaccines"},{"issue":"6","key":"10.1016\/j.vaccine.2017.12.046_b0060","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.vaccine.2010.11.079","article-title":"Yellow fever 17D-vectored vaccines expressing Lassa virus GP1 and GP2 glycoproteins provide protection against fatal disease in guinea pigs","volume":"29","author":"Jiang","year":"2011","journal-title":"Vaccine"},{"issue":"15","key":"10.1016\/j.vaccine.2017.12.046_b0065","doi-asserted-by":"crossref","first-page":"6992","DOI":"10.1128\/JVI.74.15.6992-7004.2000","article-title":"Genetic diversity among Lassa virus strains","volume":"74","author":"Bowen","year":"2000","journal-title":"J Virol"},{"issue":"4","key":"10.1016\/j.vaccine.2017.12.046_b0070","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.cell.2015.07.020","article-title":"Clinical sequencing uncovers origins and evolution of lassa virus","volume":"162","author":"Andersen Kristian","year":"2015","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.vaccine.2017.12.046_b0075","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jcv.2007.11.019","article-title":"Strain-specific antibody response to Lassa virus in the local population of West AFrica","volume":"42","author":"Emmerich","year":"2008","journal-title":"J Clin Virol"},{"key":"10.1016\/j.vaccine.2017.12.046_b0080","first-page":"75","article-title":"Lassa fever","volume":"262","author":"McCormick","year":"2002","journal-title":"Curr Top Microbiol Immunol"},{"issue":"20","key":"10.1016\/j.vaccine.2017.12.046_b0085","doi-asserted-by":"crossref","first-page":"4093","DOI":"10.1016\/j.vaccine.2007.02.038","article-title":"A ML29 reassortant virus protects guinea pigs against a distantly related Nigerian strain of Lassa virus and can provide sterilizing immunity","volume":"25","author":"Carrion","year":"2007","journal-title":"Vaccine"},{"issue":"22","key":"10.1016\/j.vaccine.2017.12.046_b0090","doi-asserted-by":"crossref","first-page":"13934","DOI":"10.1128\/JVI.79.22.13934-13942.2005","article-title":"A live attenuated vaccine for lassa fever made by reassortment of lassa and mopeia viruses","volume":"79","author":"Lukashevich","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2017.12.046_b0095","series-title":"Novel technologies for vaccine development","first-page":"61","article-title":"Aphavirus replicon vectors for prophylactic applications and cancer intervention","author":"Pushko","year":"2014"},{"issue":"4","key":"10.1016\/j.vaccine.2017.12.046_b0100","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/0264-410X(95)00168-Z","article-title":"Long-term duration of detectable neutralizing antibodies after administration of live-attenuated VEE vaccine and following booster vaccination with inactivated VEE vaccine","volume":"14","author":"Pittman","year":"1996","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2017.12.046_b0105","doi-asserted-by":"crossref","first-page":"1000160","DOI":"10.4172\/2157-7560.1000160","article-title":"Vaccine platforms to control arenaviral hemorrhagic fevers","volume":"3","author":"Carrion","year":"2012","journal-title":"J Vaccines Vaccination"},{"issue":"23","key":"10.1016\/j.vaccine.2017.12.046_b0110","doi-asserted-by":"crossref","first-page":"11677","DOI":"10.1128\/JVI.75.23.11677-11685.2001","article-title":"Individual and bivalent vaccines based on alphavirus replicons protect guinea pigs against infection with Lassa and Ebola viruses","volume":"75","author":"Pushko","year":"2001","journal-title":"J Virol"},{"issue":"2","key":"10.1016\/j.vaccine.2017.12.046_b0115","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1006\/viro.1997.8878","article-title":"Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo","volume":"2","author":"Pushko","year":"1997","journal-title":"Virology"},{"issue":"2","key":"10.1016\/j.vaccine.2017.12.046_b0120","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.virol.2005.12.001","article-title":"A recombinant Yellow Fever 17D vaccine expressing Lassa virus glycoproteins","volume":"345","author":"Bredenbeek","year":"2006","journal-title":"Virology"},{"issue":"8","key":"10.1016\/j.vaccine.2017.12.046_b0125","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/j.vaccine.2011.12.134","article-title":"Evaluation of Lassa virus vaccine immunogenicity in a CBA\/J-ML29 mouse model","volume":"30","author":"Goicochea","year":"2012","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2017.12.046_b0130","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/jmv.1890400308","article-title":"Lassa virus activity in Guinea: distribution of human antiviral antibody defined using enzyme-linked immunosorbent assay with recombinant antigen","volume":"40","author":"Lukashevich","year":"1993","journal-title":"J Med Virol"},{"key":"10.1016\/j.vaccine.2017.12.046_b0135","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.ceb.2010.05.005","article-title":"Quality and quantity control at the endoplasmic reticulum","volume":"22","author":"Hegde","year":"2010","journal-title":"Curr Opin Cell Biol"},{"key":"10.1016\/j.vaccine.2017.12.046_b0140","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/B978-0-12-385114-7.00004-0","article-title":"Measuring ER stress and the unfolded protein response using mammalian tissue culture system","volume":"490","author":"Oslowski","year":"2011","journal-title":"Methods Enzymol"},{"key":"10.1016\/j.vaccine.2017.12.046_b0145","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1101\/gad.6.3.439","article-title":"CHOP, a novel developmentally regu-lated nuclear protein that dimerizes with transcription factors C\/EBP and LAP and functions as a dominant-negative inhibitor of gene transcription","volume":"6","author":"Ron","year":"1992","journal-title":"Genes Dev"},{"issue":"1","key":"10.1016\/j.vaccine.2017.12.046_b0150","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1586\/erv.12.139","article-title":"The search for animal models for Lassa fever vaccine development","volume":"12","author":"Lukashevich","year":"2013","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2017.12.046_b0155","doi-asserted-by":"crossref","first-page":"e183","DOI":"10.1371\/journal.pmed.0020183","article-title":"Development of a new vaccine for the prevention of Lassa fever","volume":"2","author":"Geisbert","year":"2005","journal-title":"PLoS Med"},{"issue":"33","key":"10.1016\/j.vaccine.2017.12.046_b0160","doi-asserted-by":"crossref","first-page":"4267","DOI":"10.1016\/j.vaccine.2008.05.046","article-title":"Alphavirus replicon particles acting as adjuvants promote CD8+ T cell responses to co-delivered antigen","volume":"26","author":"Thompson","year":"2008","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.vaccine.2017.12.046_b0165","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.3390\/v4112514","article-title":"Advanced vaccine candidates for lassa fever","volume":"4","author":"Lukashevich","year":"2012","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2017.12.046_b0170","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1126\/science.1096378","article-title":"CD8+ T cell cross-priming via transfer of proteasome substrates","volume":"304","author":"Norbury","year":"2004","journal-title":"Science"},{"issue":"9\u201310","key":"10.1016\/j.vaccine.2017.12.046_b0175","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/j.vaccine.2003.10.003","article-title":"Induction of cytotoxic T lymphocyte activity by immunization with recombinant Semliki Forest virus: indications for cross-priming","volume":"22","author":"Huckriede","year":"2004","journal-title":"Vaccine"},{"issue":"18","key":"10.1016\/j.vaccine.2017.12.046_b0180","doi-asserted-by":"crossref","first-page":"9782","DOI":"10.1128\/JVI.00694-12","article-title":"Stable antigen is most effective for eliciting CD8+ T-cell responses after DNA vaccination and infection with recombinant vaccinia virus in vivo","volume":"86","author":"Schliehe","year":"2012","journal-title":"J Virol"},{"issue":"33","key":"10.1016\/j.vaccine.2017.12.046_b0185","doi-asserted-by":"crossref","first-page":"13426","DOI":"10.1073\/pnas.0704423104","article-title":"A lymphocytic choriomeningitis virus glycoprotein variant that is retained in the endoplasmic reticulum efficiently cross-primes CD8+ T cell responses","volume":"104","author":"Freigang","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"10.1016\/j.vaccine.2017.12.046_b0190","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/nri.2016.138","article-title":"Immunobiology of Ebola and Lassa virus infections","volume":"17","author":"Prescott","year":"2017","journal-title":"Nat Rev Immunol"},{"issue":"10","key":"10.1016\/j.vaccine.2017.12.046_b0195","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1038\/nm.4396","article-title":"Human-monoclonal-antibody therapy protects nonhuman primates against advanced Lassa fever","volume":"23","author":"Mire","year":"2017","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.vaccine.2017.12.046_b0200","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.virol.2003.12.013","article-title":"Old and New World arenaviruses share a highly conserved epitope in the fusion domain of the glycoprotein 2, which is recognized by Lassa virus-specific human CD4+ T-cell clones","volume":"321","author":"Meulen","year":"2004","journal-title":"Virology"},{"issue":"5","key":"10.1016\/j.vaccine.2017.12.046_b0205","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1128\/JVI.74.5.2186-2192.2000","article-title":"Characterization of human CD4+ T-cell clones recognizing conserved and variable epitopes of the Lassa virus nucleoprotein","volume":"74","author":"ter Meulen","year":"2000","journal-title":"J Virol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17318078?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17318078?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:24:43Z","timestamp":1759400683000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X17318078"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["S0264410X17318078"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.12.046","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Alphavirus vector-based replicon particles expressing multivalent cross-protective Lassa virus glycoproteins","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.12.046","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}